Does your doctor have enough functioning brain cells to spend 45 minutes with this CME to see if anything here will get your spasticity cured? I see nothing useful here since they are talking 'management' NOT CURE!
Overburdened, Undertreated: Developments in the Patient-Centered Management of Spasticity in Multiple Sclerosis
This activity is supported by an educational grant from AbbVie.
Activity Overview
Over 80% of patients with multiple sclerosis (MS) experience related spasticity. This symptom can be debilitating for both physical and non-physical daily function. Yet, despite the high prevalence and impact of spasticity, a substantial portion of affected patients remain unrecognized and undertreated.
Even when cases are accurately identified, achieving adequate treatment is challenging. Many of the most common therapies are accompanied by unpleasant side effects (e.g., insomnia, muscle weakness) that often lead to their discontinuation. Though botulinum neurotoxin (BoNT) is among those shown to be effective, optimal timing and patient selection are needed to maximize its benefits. The current activity seeks to help clinicians circumvent unpleasant side effects and undertreatment through personalizing and adjusting therapy based on individual patient needs. In collaboration with the Multiple Sclerosis Foundation, 239 patients with MS-related spasticity were surveyed to give deeper insight into evidence-based strategies to improve patient outcomes.
Target Audience
The target audience for this initiative includes general neurologists, physiatrists, nurse practitioners, physician assistants, and other healthcare professionals involved in the diagnosis and long-term management of patients with MS-related spasticity.
Learning Objectives
Upon completion of the educational activity, participants should be able to:
- Identify concerns and preferences of patients with MS surrounding the experience and treatment of spasticity, and apply this information in the development of improved patient-driven management strategies
- Assess diverse presentations of MS-related spasticity to accurately identify patients early in the disease course and intervene accordingly
- Determine patient-centered strategies to target individual treatment goals using both non-pharmacological and medication-based approaches
- Analyze key considerations for the effective use of BoNT injections to maximize their benefits and ensure patient satisfaction with treatment
Presenting Faculty
Scott Newsome, DO, MSCS, FAAN, FANA (Chair)
Director, Neurosciences Consultation and Infusion Center Stiff Person Syndrome Center
Johns Hopkins Neuroimmunology and Neurological Infectious Disease Fellowship
Co-Director, Multiple Sclerosis Experimental Therapeutics Program
Associate Professor of Neurology
Baltimore, MD
Daniel S. Bandari, MD, MS
Director, Multiple Sclerosis Center of California & Research Group
Clinical Assistant Professor of Neurology & Neuro-immunology
University of Southern California, Keck School of Medicine
Laguna Hills, CA
Lisa Fox, PA-C
Senior Physician Assistant, Neurology/Neuroimmunology
Associate Director, Neurology Outpatient Infusion Center
Johns Hopkins University
Baltimore, MD
No comments:
Post a Comment